文献速递主动脉疾病

EVAR术后瘤囊缩小:三种支架的多中心比较数据

Sac Shrinkage after Endovascular Aneurysm Repair: Multicentre Comparative Data from Three Stent Grafts.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-06-12

这项回顾性多中心队列研究分析了444例AAA患者EVAR术后一年内的瘤囊缩小情况,比较Aorfix与Endurant、Excluder支架。Aorfix组瘤囊缩小率为52.1%,高于Endurant组的32.8%和Excluder组的34.0%(p=.003)。多变量分析显示Aorfix支架、较小近端瘤颈直径和通畅腰动脉数量少于四支是瘤囊缩小的正向因素。

要点

  • Aorfix组一年内瘤囊缩小率52.1%,高于Endurant组32.8%和Excluder组34.0%(p=.003)。
  • Aorfix支架、较小近端瘤颈直径、通畅腰动脉少于四支是瘤囊缩小的正向因素。
  • 瘤囊缩小组再干预和T1aEL发生率低于无缩小组,瘤囊缩小是EVAR术后良好替代指标。

核心结论

  • Aorfix组一年内瘤囊缩小优于Endurant组和Excluder组,瘤囊缩小是EVAR术后免于再干预和T1aEL的良好替代指标。
  • 但回顾性研究设计可能引入偏倚。

研究设计与样本

  • 回顾性多中心队列研究,分析2014至2021年间444例AAA患者EVAR术后数据。
  • 患者分别接受Aorfix(88例)、Endurant(191例)或Excluder(165例)支架治疗。

主要发现

  • Aorfix组、Endurant组和Excluder组一年内瘤囊缩小率分别为52.1%、32.8%和34.0%(p=.003)。
  • 多变量分析显示Aorfix支架(参照Endurant,p<.001;参照Excluder,p=.010)、较小近端瘤颈直径(p=.004)和通畅腰动脉数量少于四支(p=.033)是瘤囊缩小的正向因素。
  • 一年内瘤囊缩小组的再干预率和T1aEL率低于无缩小组。
  • 十年ARD率在无缩小组为3.8%,在缩小组为0.7%(p=.29)。

关键数值与推荐

  • 瘤囊缩小定义为最大动脉瘤直径减少≥5mm。

临床怎么用

  • EVAR术后一年内瘤囊缩小情况可作为评估治疗成功的替代指标,Aorfix支架显示更高的瘤囊缩小率。

局限性

  • 原文述回顾性研究设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Abdominal aortic aneurysm (AAA) sac shrinkage has been reported as a surrogate marker of treatment success after endovascular aneurysm repair (EVAR). This study aimed to compare sac shrinkage after treatment with the Aorfix stent graft with that of Endurant and Excluder devices. METHODS: This retrospective, multicentre cohort study analysed data for 444 patients with AAA after EVAR who were treated with Aorfix, Endurant, or Excluder devices between 2014 and 2021. Sac shrinkage was defined as a decrease in the maximum aneurysm diameter of ≥ 5 mm. Primary endpoints included sac shrinkage and factors related to sac shrinkage within one year after EVAR. Secondary endpoints included re-intervention, type Ia endoleak (T1aEL), aneurysm related death (ARD), and overall survival. RESULTS: Of the 444 patients, 88 were treated with Aorfix, 191 with Endurant, and 165 with the Excluder. Sac shrinkage rates within one year in the Aorfix, Endurant, and Excluder groups were 52.1%, 32.8%, and 34.0%, respectively (p = .003). Multivariable analysis revealed that Aorfix device (ref. Endurant, p < .001; ref. Excluder, p= .010), smaller proximal neck diameter (p= .004), and number of patent lumbar arteries less than four (p= .033) were positive factors for sac shrinkage within one year. Re-intervention and T1aEL rates were lower in the sac shrinkage group within one year than in the group without sac shrinkage within one year. The ARD rate at ten years was 3.8% in the no shrinkage group and 0.7% in the shrinkage group (p= .29). CONCLUSION: Sac shrinkage within one year was better in patients treated with the Aorfix device than in those treated with Endurant or Excluder devices, and sac shrinkage was a good surrogate marker for freedom from re-intervention and T1aEL after EVAR. However, the retrospective study design may have introduced.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Morisaki K, Matsuda D, Nakayama K, et al. Sac Shrinkage after Endovascular Aneurysm Repair: Multicentre Comparative Data from Three Stent Grafts. Eur J Vasc Endovasc Surg. 2025. PMID: 40516811. doi:10.1016/j.ejvs.2025.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。